118 related articles for article (PubMed ID: 2867770)
21. [Effect of sulfasalazine and its metabolites on prostaglandin and leukotriene liberation from human synovial tissue].
Wittenberg HR; Kleemeyer K; Peskar BM; Peskar BA
Wien Klin Wochenschr; 1991; 103(2):34-9. PubMed ID: 1673814
[TBL] [Abstract][Full Text] [Related]
22. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species.
Miyachi Y; Yoshioka A; Imamura S; Niwa Y
Gut; 1987 Feb; 28(2):190-5. PubMed ID: 2881849
[TBL] [Abstract][Full Text] [Related]
23. New metabolites of the drug 5-aminosalicylic acid. II. N-formyl-5-aminosalicylic acid.
Tjørnelund J; Hansen SH; Cornett C
Xenobiotica; 1991 May; 21(5):605-12. PubMed ID: 1949893
[TBL] [Abstract][Full Text] [Related]
24. Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine.
Allgayer H; Eisenburg J; Paumgartner G
Eur J Clin Pharmacol; 1984; 26(4):449-51. PubMed ID: 6428914
[TBL] [Abstract][Full Text] [Related]
25. The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.
Azadkhan AK; Truelove SC; Aronson JK
Br J Clin Pharmacol; 1982 Apr; 13(4):523-8. PubMed ID: 6121576
[TBL] [Abstract][Full Text] [Related]
26. Effect of sulphasalazine and its metabolites on mitogen induced transformation of lymphocytes--clues to its clinical action?
Sheldon P; Webb C; Grindulis KA
Br J Rheumatol; 1988 Oct; 27(5):344-9. PubMed ID: 2902897
[TBL] [Abstract][Full Text] [Related]
27. Increased suppressor cell activity in inflammatory bowel disease.
Holdstock G; Chastenay BF; Krawitt EL
Gut; 1981 Dec; 22(12):1025-30. PubMed ID: 6119275
[TBL] [Abstract][Full Text] [Related]
28. 5-Aminosalicylic acid or sulphapyridine. Which is the active moiety of sulphasalazine in rheumatoid arthritis?
Taggart AJ; Neumann VC; Hill J; Astbury C; Le Gallez P; Dixon JS
Drugs; 1986; 32 Suppl 1():27-34. PubMed ID: 2877851
[TBL] [Abstract][Full Text] [Related]
29. [New salicylic acid derivatives in the treatment of inflammatory intestinal diseases].
Kovács A
Orv Hetil; 1991 Jun; 132(24):1317-21. PubMed ID: 1677465
[TBL] [Abstract][Full Text] [Related]
30. The oxygen-centered radicals scavenging activity of sulfasalazine and its metabolites. A direct protection of the bowel.
Prónai L; Yukinobu I; Láng I; Fehér J
Acta Physiol Hung; 1992; 80(1-4):317-23. PubMed ID: 1364279
[TBL] [Abstract][Full Text] [Related]
31. Estimation of 5-aminosalicylic acid and its metabolite in human serum by front-face fluorometry: a simple and sensitive method.
Hirsch RE; Lin MJ; Das KM
J Lab Clin Med; 1990 Jul; 116(1):45-50. PubMed ID: 2376696
[TBL] [Abstract][Full Text] [Related]
32. Amino acid derivatives of 5-ASA as novel prodrugs for intestinal drug delivery.
Clerici C; Gentili G; Boschetti E; Santucci C; Aburbeh AG; Natalini B; Pellicciari R; Morelli A
Dig Dis Sci; 1994 Dec; 39(12):2601-6. PubMed ID: 7995185
[TBL] [Abstract][Full Text] [Related]
33. Sulphasalazine, sulphapyridine or 5-aminosalicylic acid--which is the active moiety in rheumatoid arthritis?
Bird HA
Br J Rheumatol; 1995 Nov; 34 Suppl 2():16-9. PubMed ID: 8535642
[TBL] [Abstract][Full Text] [Related]
34. Synthesis and in vitro/in vivo evaluation of 5-aminosalicyl-glycine as a colon-specific prodrug of 5-aminosalicylic acid.
Jung YJ; Lee JS; Kim YM
J Pharm Sci; 2000 May; 89(5):594-602. PubMed ID: 10756325
[TBL] [Abstract][Full Text] [Related]
35. Disposition of 5-aminosalicylic acid from 5-aminosalicylic acid-delivering drugs during accelerated intestinal transit in healthy volunteers.
Rijk MC; van Hogezand RA; van Schaik A; van Tongeren JH
Scand J Gastroenterol; 1989 Dec; 24(10):1179-85. PubMed ID: 2574905
[TBL] [Abstract][Full Text] [Related]
36. The prophylactic effect of 5-aminosalicylic acid and salazosulphapyridine on degraded-carrageenan-induced colitis in guinea pigs.
Jensen BH; Andersen JO; Poulsen SS; Skov Olsen P; Nørby Rasmussen S; Hansen SH; Hvidberg EF
Scand J Gastroenterol; 1984 May; 19(3):299-303. PubMed ID: 6146186
[TBL] [Abstract][Full Text] [Related]
37. In vitro effects of sulphasalazine, azodisal sodium, and their metabolites on Clostridium difficile and some other faecal bacteria.
Sandberg-Gertzen H; Kjellander J; Sundberg-Gillå B; Järnerot G
Scand J Gastroenterol; 1985 Jun; 20(5):607-12. PubMed ID: 2862692
[TBL] [Abstract][Full Text] [Related]
38. 5-Aminosalicylic acid derivatives. Clinical and pharmaceutical evaluation.
Christensen LA; Jacobsen BA
Neth J Med; 1989 Jun; 35 Suppl 1():S3-10. PubMed ID: 2702310
[TBL] [Abstract][Full Text] [Related]
39. 5-ASA-glutamate protects rats from inflammatory bowel disease induced by intracolonic administration of trinitrobenzensulfonic acid.
Clerici C; Gentili G; Pellicciari R; Gresele P; Mezzasoma AM; Giansanti M; Clementi M; Bartoli G; Balò S; Modesto R; Aburbeh AG; Morelli O; Morelli A
Ital J Gastroenterol Hepatol; 1998 Aug; 30(4):385-90. PubMed ID: 9789134
[TBL] [Abstract][Full Text] [Related]
40. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
